Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06211413 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06211413 · ClinicalTrials.gov record · last posted 2026-03-23

Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors

Study acronym: SENTINEL
StatusEnrolling by Invitation
PhaseNot specified
Started2024-02-07
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms. SENTINEL is an observational study that will use wearable technology to monitor heart rhythm and blood pressures at home to better understand how frequently patients are experiencing high blood pressure and/or abnormal heart rhythms.

Amendment record 4 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 4 times since 2024-01-09; most recent amendment 2026-03-19. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-02-22
Status change Not Yet Recruiting→Enrolling by Invitationv2
Trial Details
NCT Number NCT06211413
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
Enrollment 50 participants
Start Date 2024-02-07
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-23